Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients

Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients Publisher Pubmed

Kianfar N¹ ; Dasdar S¹ ; Mahmoudi H¹ ; Tavakolpour S¹ ; Balighi K¹ ; Daneshpazhooh M¹

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Dermatological Treatment Published:2020

Abstract

Background: Little data are available concerning the outcome of rituximab (RTX) therapy in pediatric patients with autoimmune bullous diseases (AIBDs). Objective: We sought to evaluate safety and efficacy of RTX administration in pediatric patients with AIBDs and to assess first-line RTX therapy in pemphigus patients. Methods: AIBD patients consisting of 12 pemphigus patients and a patient with bullous pemphigoid who received RTX before the age of 18 were enrolled. Detailed information regarding patients’ outcome after the first RTX cycle was assessed. Results: The mean age of the patients at RTX infusion was 15 ± 2 years. Six patients in the pemphigus group received RTX as first-line therapy. In pemphigus patients: complete remission (on minimal therapy) was achieved by seven patients, partial remission (on minimal therapy) and complete remission (off therapy) were achieved by three patients and one, respectively. Relapse occurred in nine patients, which were mostly mild. Likewise, the BP patient received RTX with a good clinical response. The observed adverse events were mostly mild infusion reactions and a case of sepsis. Conclusion: Rituximab is safe and effective in childhood/juvenile patients with AIBDs. Furthermore, RTX can be used as first-line treatment in pediatric patients with pemphigus. © 2020, © 2020 Taylor & Francis Group, LLC.

Related Docs

View other Related Docs

1. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)

2. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

3. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)

4. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)

5. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)

6. Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study, International Immunopharmacology (2021)

7. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)

8. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris, EXCLI Journal (2015)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (33)

Hamid Reza Mahmoodi (25)

Style	Citing Format
MLA	Kianfar N, et al.. "Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients." Journal of Dermatological Treatment, vol. , no. , 2020, pp. 1-6.
APA	Kianfar N, Dasdar S, Mahmoudi H, Tavakolpour S, Balighi K, Daneshpazhooh M (2020). Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients. Journal of Dermatological Treatment, (), 1-6.
Chicago	Kianfar N, Dasdar S, Mahmoudi H, Tavakolpour S, Balighi K, Daneshpazhooh M. "Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients." Journal of Dermatological Treatment , no. (2020): 1-6.
Harvard	Kianfar N et al. (2020) 'Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients', Journal of Dermatological Treatment, (), pp. 1-6.
Vancouver	Kianfar N, Dasdar S, Mahmoudi H, Tavakolpour S, Balighi K, Daneshpazhooh M. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients. Journal of Dermatological Treatment. 2020;():1-6.
BibTex	@article{ author = {Kianfar N and Dasdar S and Mahmoudi H and Tavakolpour S and Balighi K and Daneshpazhooh M}, title = {Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients}, journal = {Journal of Dermatological Treatment}, volume = {}, number = {}, pages = {1-6}, year = {2020} }
RIS	TY - JOUR AU - Kianfar N AU - Dasdar S AU - Mahmoudi H AU - Tavakolpour S AU - Balighi K AU - Daneshpazhooh M TI - Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients JO - Journal of Dermatological Treatment VL - IS - SP - 1 EP - 6 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract